Debra Sieminski
SVP, Medical Affairs

Ms. Sieminski brings 20 years of industry expertise in medical and clinical affairs in multiple therapeutic areas; including hepatology and infectious diseases, as well as hematologic malignancies and a variety of solid tumors.

Before joining Terns, she was the Head of US Medical Affairs at Stemline Therapeutics, a Menarini Group company, where she was responsible for leading the development and execution of the US medical affairs strategy and launch readiness for ELZONRIS (tagraxofusp) and ORSERDU (elacestrant). She previously held leadership roles of increasing responsibility at Idenix, Vertex, and Intercept Pharmaceuticals.

Ms. Sieminski earned a bachelor's degree from Pennsylvania State University and master’s degrees from the University of Maryland and Eastern Virginia Medical School.